View abstract guidelines below:​

 

​The content of the abstract must be related to one of the following categories. To ensure smooth scoring of papers, the topic of your work must be selected during the submission process.

​

Main Categories

• Acquired and Critical Care Bleeding

• Antithrombotic and Fibrinolytic Therapies

• Arterial Disease

• Coagulation Factors and Cofactors

• Coagulation Modifiers, Anticoagulants, and von Willebrand Factor

• Diagnostics, OMICs, and Advanced Technologies

• Fibrinogen, Factor XIII, and Fibrinolysis

• Hemophilia and other Inherited Bleeding Disorders and Inhibitors

• Nurses and Allied Health

• Pediatric Hemostasis and Thrombosis

• Platelet Disorders

• Platelets and Megakaryocytes

• Vascular Biology, Blood Cells, and Immunothrombosis

• Venous Disease

• Women's Hemostasis and Thrombosis

 

Sub-categories

Acquired and Critical Care Bleeding

• Antithrombotic Drug-Associated Bleeding

• Coagulopathy of Liver and Renal Disease

• Coagulopathy of Other Systemic Diseases

• Coagulopathy of Trauma

• Massive Transfusion Management

• Perioperative Bleeding

Antithrombotic and Fibrinolytic Therapies

• Current Anticoagulants

• Future Anticoagulants

• Current Antiplatelet Agents

• Future Antiplatelet Agents

• Current and Future Fibrinolytic Therapies

• Antithrombotic Stewardship

Arterial Disease

• Atrial Fibrillation

• Cerebrovascular Disease

• Coronary Artery and Other Cardiac Diseases

• Peripheral Artery Disease

Coagulation Factors and Cofactors

• Common Pathway

• Contact Pathway

• Non-hemostatic Roles of Coagulation Proteins

• Protein Structure and Function

• Synthesis and Biochemistry

• TF and TFPI Pathway

Coagulation Modifiers, Anticoagulants, and von Willebrand Factor

• ADAMTS13 and Other Proteases

• Antithrombin and Other Serpins

• Non-hemostatic Roles of Anticoagulant Proteins

• Protein C/S Pathway

• von Willebrand Factor

Diagnostics, OMICs, and Advanced Technologies

• Artificial Intelligence/Machine Learning

• Genomics and Transcriptomics

• Mathematical and Computational Models

• Novel Experimental Models of Hemostatic and Thrombotic Diseases

• Novel Clinical Laboratory Diagnostic Methods

• Proteomics, Metabolomics, and Lipidomics

Fibrinogen, Factor XIII, and Fibrinolysis

• Factor XIII and Other Transglutaminases

• Fibrinogen Structure and Function

• Fibrinolysis and Proteolysis

Hemophilia and other Inherited Bleeding Disorders and Inhibitors

• Acquired Factor Deficiencies

• Gene Therapy

• Congenital Hemophilia with Inhibitors

• Joint Health

• Novel Hemostatic Therapies

• Rare Factor Deficiencies

• Vascular Disorders

• Von Willebrand Disease

Nurses and Allied Health

• Nurses and Allied Health

Pediatric Hemostasis and Thrombosis

• Bleeding and Thrombotic Issues in Adolescence

• Neonatal Coagulation Disorders

• Pediatric Bleeding and Thrombosis

• Perioperative and Critical Care

Platelet Disorders

• Acquired Platelet Disorders

• Immune Thrombocytopenia - ITP, HIT, PF4 Antibodies

• Inherited Platelet Disorders

• Myeloproliferative Neoplasms and Clonal Disorders

• Thrombotic Microangiopathy

Platelets and Megakaryocytes

• Megakaryocyte Biology

• Non-hemostatic Roles of Platelets

• Platelet Biology

• Receptors and Signaling

Vascular Biology, Blood Cells, and Immunothrombosis

• Blood Vessel Structure and Function

• Coagulation and Cancer

• Coagulation and Non-Malignant Comorbidities

• Endothelial Cell Biology

• Extracellular Vesicles

• Infection and Immunity in Immunothrombosis and Bleeding

• Inflammation and Thrombosis

• Red Cell Disorders and Coagulation

Venous Disease

• Cancer-associated Thrombosis

• Deep and Superficial Venous Thrombosis

• Long-term Consequences of VTE - CTEPH, PTS, etc.

• Pulmonary Embolism

• Thrombophilia

• Unusual Site VTE

Women's Hemostasis and Thrombosis

• Hormonal Modulation of Coagulation

• Menstrual Bleeding Disorders

• Pregnancy

• Hormonal Modulation of Coagulation

• Menstrual Bleeding Disorders

• Pregnancy

​

Statement on the Use of AI

The ISTH recognizes the use of generative artificial intelligence (AI) as a powerful tool for educators and researchers and encourages its responsible and ethical use. If any form of generative AI is utilized for this abstract, it must be clearly acknowledged. It is expected that authors will review any AI-generated copy, figures, images, citations, or statements for accuracy and edit accordingly. The use of AI must be documented during the abstract submission process as well as disclosed to the audience if the abstract is accepted for presentation.

​

Maximize your research impact with simultaneous publication

Simultaneous publication of studies presented at the ISTH Congress offers an exciting opportunity to broaden the impact of your research. By sharing your findings at both the Congress and in a peer-reviewed journal, you can expand visibility, reach a wider global audience and ensure your work contributes more fully to advancing science and patient care.

 

Consider submitting your abstract for simultaneous publication. Review the opportunities and rules outlined here to help guide your submission.

​

How to Submit an Abstract

• Delegates who would like to present their work at the congress, either orally or as a poster, are invited to submit an abstract for consideration by the Scientific Committee.

• ISTH Members and Non-Members are invited to submit abstracts.

• There are no fees to submit an abstract during the general submission period. The Late-Breakthrough abstract submission, however will incur a fee per abstract submission.

• Abstracts can only be submitted online via the abstract submission website that can be found in the section “Abstract Guidelines” on the official ISTH Congress website. Abstracts sent by post or email will not be accepted. No exceptions will be made.

• The submitter will be required to create a new user account in order to submit an abstract. Once logged in, you will be able to submit your abstract. Please note if you used the abstract submission in 2026, your information was saved and you can login using the same credentials.

• Abstracts can be saved in "Draft” status and be re-edited and modified until the submission deadline (January 11, 2027 at 17:00 U.S. EST)

  • You can still make edits to abstracts that have been submitted, but you will need to re-submit it before the deadline to be considered. Please ensure that your abstract has been properly submitted by the deadline. Draft submissions will not be considered.

• The submitted/draft abstracts cannot be edited after the submission deadline.

• Only abstracts that have been submitted properly will be considered for the congress.

• Any technical questions regarding the submission website should be sent to abstracts@isth.org.

​

General Guidelines

• The abstract must address scientific questions, detail clinical observations, or contain primary scientific data.

• NEW! Case reports may be submitted as a detailed scientific medical description of an individual patient’s condition, diagnosis, treatment, and outcome. Case reports are intended to document unique, rare, or noteworthy clinical cases that provide new insights into diseases, therapies, adverse events, or diagnostic approaches. Occasional case reports that demonstrate exceptional clinical significance or have the potential to change clinical practice may be considered for presentation at the ISTH Congress. Unless a case report is deemed exceptional, highly novel, or practice-changing by the review committee, it will be accepted for publication only and will not be eligible for poster presentation.

• Abstracts should be submitted in clear English to allow the reviewers to focus on the scientific content of the abstract. Abstracts submitted in any language other than English will be automatically rejected. Non-English-speaking authors are encouraged to have their abstract checked for grammar and spelling.

• Please ensure your abstract does not contain spelling, grammar, or scientific mistakes, as it will be reproduced exactly as submitted. Linguistic accuracy is your responsibility. No proof reading will be done.

• Do not slice results from the same study into multiple abstracts. The Scientific Committee reserves the right to reject abstracts when inappropriate slicing of data is suspected. Similarly, do not submit a copy or close copy of an abstract under more than one (1) topic. Abstracts that appear to be submitted multiple times under different topics will be rejected.

• All research and studies in submitted abstracts that involve human subjects or experimental animals must comply with the Declaration of Helsinki.

• No revisions can be made after the abstract deadline. To ensure the integrity of the review process, revisions to abstracts will not be accepted after the abstract submission deadline.

• Requests for changes to the abstract presentation schedule will not be accepted due to the large number of presentations. Presenting Authors should be prepared to present their work at the date and time listed in their acceptance notification or should provide the ISTH with an alternate presenter from the list of their co-authors by May 3, 2027.

​

Presenting Author Information and Responsibilities

• The presenting author must be at least 18 years of age at the time of the presentation and is responsible for fees associated with registering and traveling to the congress to present their work.

• The presenting author may not be an employee or owner of a commercial interest or have any other actual or perceived conflicts of interest (COIs) as determined by the current accreditation body for the ISTH. Any abstract where the presenting author is deemed to have a COI will not be considered for an Oral Communication presentation.

• The presenting author may serve as the presenter for up to 3 poster presentations during the congress (with a maximum of 2 posters per day). If an author is listed as the presenter on more than 3 posters, they will need to name a co-author to present on their behalf or the poster will be withdrawn/not accepted.

• The presenting author serves as the primary contact for all correspondence about the abstract. No other co-authors on the abstract will receive correspondence from the ISTH. The presenting author is responsible for forwarding any ISTH communications about the abstract/presentation to the respective co-authors.

• The presenting author of the abstract must be registered for the congress. The abstract(s) will be withdrawn if registration is not completed by May 3, 2027.

  • The submission of an abstract constitutes a formal commitment by the submitting (presenting) author to present the abstract in-person (if accepted) in the session and the time assigned by the Scientific Committee. Registration fees will not be waived and no virtual presentations will be allowed.

​

ISTH Embargo Policy

You can view the ISTH Embargo Policy here.

 

Prior Publication

Authors will be permitted to submit their abstract to the ISTH Congress and another journal/meeting as long as the data in the abstract has not been published/presented to a scientific audience at the time of submission. Press releases may be allowed only if general information and no primary detailed data is included.

 

Abstracts submitted to regional or national meetings (no larger than 2,000 attendees) can be submitted to the ISTH Congress for consideration for inclusion in the program.

 

If you have questions regarding prior publication please contact us at abstracts@isth.org.

​

Preparing an Abstract for Submission
Authors and Co-Authors

• The submitter or presenting author is responsible for ensuring that all authors have read the abstract and agreed to be co-authors.

• The presenting author of the abstract must be registered for the congress. Abstract(s) will be withdrawn if registration is not completed by the presenting author by May 3, 2027.

• A maximum of 20 authors is permitted on each abstract.

• Adding Co-authors: please fill out the family names, first names, and institution, city, country and email addresses of each co-author.

• Based on current accreditation guidelines, if the presenting author is employed by industry or has an unresolvable conflict of interest, an alternate and unconflicted presenter must be named if the abstract is selected for presentation in an Oral Communication session.

• The presenting author may not be a patient or patient advocate.

 

Conflict of Interest

• It is the intent of the ISTH to provide high-quality sessions focused on educational content that is free from commercial influence or bias. Thus, the submitting/presenting author of an abstract is required to declare any potential conflicts of interest for the presenting author during abstract submission.

• The submitting/presenting author should be prepared to have each co-author complete and sign a conflict of interest disclosure per accreditation requirements.

Abstract Body

• For standardization, the acceptable length of the abstract is a maximum of 350 words. This does not include the author’s details or the title.

• Title: Clearly indicate the nature of the investigation. The abstract title and text may not contain trade names. The Scientific Committee reserves the right to replace trade names in accepted abstracts. Maximum word count for the title is 50 words.

• Background

• Aims

• Methods: Which should contain sufficient information to be able to understand the experimental design, the analytical techniques and the statistics used in the study

• Results: Which should contain objective data to answer the scientific question(s). A maximum of two total tables or figures may be submitted with this section. Please be sure to number each table and figure and cite each table and figure in the abstract text.

• Conclusion: Which should provide only conclusions of the study directly supported by the results, along with implications for clinical practice, avoiding speculation and overgeneralization.

• Other Items for Consideration

  • In clinical studies, please state whether informed consent was obtained and whether the study was approved by a recognized medical ethics committee.

  • If the research included in your abstract was supported by a pharmaceutical or diagnostics company, you can indicate this when submitting your abstract.

  • Please indicate the funding agency of your work if applicable. There is not a specific area to enter this information, it will need to be included as part of the abstract text in the Conclusion.

  • Abbreviations should be defined.

  • If off-label use of drugs was involved in the study, please state this clearly.

Figures and Table

• Figures and tables may be submitted with a maximum file size is 2 MB w. Figures are allowed in the following formats: PNG, GIF, JPG.

• Your abstract may contain two (2) figures or tables; this can be a combination of the following: two (2) figures, two (2) tables, or one (1) figure and one (1) table.

• You will be asked to include a caption for each of your figures/tables to be included as part of the formal published abstract supplement. The caption(s) for figures/tables is included in the 350 words allotted for the abstract.

​

After Submission
An international panel of experts will review the abstracts. Each abstract will be reviewed by 3-5 different experts. Abstracts may be selected for oral presentation, poster presentation, publication only or will be rejected. Only the presenting author will be notified in late March 2027, to the email address provided during submission, as to whether or not their abstract has been accepted.

The reviewers will judge the abstracts according to the following criteria:

• Is the abstract original?

• Does it address an important scientific question?

• Is the abstract clearly written with all salient facts?

• Does the work adhere to ethical guidelines?

• Is there evidence of statistical method if appropriate?

• Are the conclusions justified by the results?

​Please note:

• No revisions can be made after the abstract deadline. To ensure the integrity of the review process, revisions to abstracts will not be accepted after the abstract submission deadline. This is inclusive of any changes to the list of co-authors.

• The highest quality abstracts will be selected for an oral presentation.

• Oral Presentation: Presenting authors of abstracts selected for an oral presentation will be informed about the date and time of the session. The presenting author will be required to be in-person and agree to have their recorded presentation available on the virtual platform for 30 days post congress. It will then be transferred to the ISTH Academy perpetually. Presenters will have the option to hide slides if they would like to. No live virtual presentations will be offered and presentation guidelines will be made available online one (1) month prior to the congress.

• Poster Presentation: Poster presenters will be informed about the date and time of the poster session. The presenting author will be required to be in-person. No virtual poster presentations will be offered. Poster guidelines will be made available online in May 2027. Posters will be organized using the topics chosen by the submitter in the online system.

• All accepted abstracts will be published online two (2) weeks prior to the ISTH 2027 Congress on Friday, June 11, 2027 at 17:00 EST (U.S.) on the ISTH 2027 Itinerary Planner, except Late-Breakthrough abstracts which will be made available on the day(s) of the Late-Breakthrough Oral Communication session(s).

• All accepted and confirmed abstracts will also be published as an addendum supplement to the ISTH open access journal, Research and Practice in Thrombosis and Haemostasis (RPTH) and will be made available on the ISTH 2027 Congress website by October 2027.

• No Show Poster: If your abstract is awarded a poster presentation and you confirm participation at the congress, but then are not physically present at your poster board at the congress without prior notification to the ISTH, your submission(s) will be noted as a ‘No Show Poster’. This may jeopardize any future poster presentations awarded to you. We thank you for adhering to the published confirmation deadline (May 3, 2027), however, if you are no longer able to attend the congress after the confirmation deadline, the ISTH does accept cancellations on a case-by-case basis. Please notify us by emailing abstracts@isth.org to avoid any consequences.

​

Withdrawal Policy
If authors wish to withdraw their abstracts from presentation or publication, they are required to notify ISTH via e-mail to abstracts@isth.org before May 3, 2027. Withdrawn abstracts will not be presented or published.

 

Travel Awards
The ISTH offers two (2) different awards that are provided in the form of travel awards. The Early Career Award and Reach-the-World Award are available to those who are the presenting authors on an abstract.

Click here to learn more.

 

Technical Requirements
The online abstract submission system works best with Google Chrome and Mozilla Firefox. Cookies and JavaScript need to be enabled.

 

Language Setting of Your Keyboard
The keyboard configuration of computers in non-Western countries may cause problems with the printing of the abstracts when special non-Western characters are used. To avoid these problems the language setting of your computer should be changed.

To do this select "Start" then Settings", then "Control Panel" and then choosing "Keyboard." Once in this menu, set the language of your computer to English (United States) or US (International). Next, open MS Word (or the word processing software you are using) and set the font type to Arial.  

In the preparation of your abstract, if you require certain special characters that are not available, (e.g. '±', '®', 'μ'), use the insert symbol feature (special characters). To do this, select Arial as the font (unicoded, if possible), then select the required character, and copy and paste the symbol into the text of the abstract. If a special character is still not available, describe the character, e.g. 'alpha’.